‹ News Blitz Economy Settled

Specified Indian medicines escape the US 100% drug tariff

English हिंदी ಕನ್ನಡ മലയാളം தமிழ் తెలుగు

First brief 29 Sep, 2:17 pm IST Updated 29 Sep, 2:17 pm IST 1 development 3 min read Latest ↓

Medicines; representative photo — epSos.de · CC BY 2.0

Where it stands

Certain medicines made in India can enter the United States without its new 100% drug-import tariff. The relief covers specified groups, including fertility medicines and some treatments for rare diseases. It also covers the ingredients used in qualifying medicines. India appears on the US Commerce Department's list of places eligible for this relief. The distinction matters as the tariff begins on 29 September 2026 for companies not covered by an earlier start date. A US buyer importing a qualifying Indian medicine avoids this extra tax. That removes a possible cost increase which could have made the Indian product harder to sell. It does not mean that every Indian medicine receives a new tax exemption. Generic medicines were already outside this particular tariff. These are medicines sold as approved alternatives to an original drug, usually after the relevant patent protection ends. The new clarification is especially relevant to specified medicines that would otherwise face the tariff on patented products. Patients' final bills also depend on other costs, so the exemption alone does not promise a price cut.

Background

A medicine often passes through several businesses before reaching a patient. A manufacturer makes it, an importer brings it into another country, and distributors supply hospitals or pharmacies. An import tax is collected at the border. The importer pays it, although businesses may share the cost or pass some of it on through higher prices. For example, suppose a covered shipment has a customs value of $100. A 100% tariff would add $100 at the border, before other applicable costs. If that shipment qualifies for the zero rate, this particular $100 charge is absent. The example explains the tax calculation; it is not a prediction that a patient's medicine bill will double or halve. The US announced the pharmaceutical tariff in April. Its stated aim was to reduce reliance on foreign supplies and encourage medicine production inside the country. The measure mainly covers specified patented medicines and their ingredients. A patent gives its holder a legal right to stop others from using the protected invention without permission for a limited period. Alongside the tariff, the US created exceptions for certain medicines and trade partners. The September notice identifies eligible product groups and includes India among the eligible places of origin. Both conditions matter: the medicine must qualify, and its origin must meet the rules. An Indian exporter of a qualifying product therefore has a different position from an exporter of another patented medicine.

How it developed

23 September 2026; eligibility notice issued

How it started
India is included, but the product must also qualify

The Commerce Department listed the places whose qualifying specialty medicines can receive a zero rate under this tariff. India is on that list. The categories include fertility drugs, gene therapies and certain medicines for rare diseases. For the rare-disease category, all approved uses of the medicine must meet the notice's condition. The notice also covers specified animal-health products and associated ingredients. These are defined categories, not a blanket exemption for everything sold by a pharmaceutical company. Importers need to identify which category and origin rules apply to the actual shipment.

US Department of Commerce US Food and Drug Administration Business Standard / PTI
29 September 2026; tariff starts for remaining companies

New fact
The wider start date makes the exemption immediately relevant

The April proclamation set two start dates. Listed companies came under the measure on 31 July; the remaining companies come under it on 29 September. Qualifying products receive the applicable exception rather than the standard 100% rate. For an Indian supplier, the practical question is therefore which rule covers the shipment, not simply whether medicines face a tariff. Generic products remain outside this particular measure. Other patented products may face different rates or company-specific arrangements under the proclamation.

White House US Department of Commerce

Why it matters for UPSC

GS2 · India–US tradeGS3 · Import duties

For GS2 and GS3, follow how a US import tax affects an Indian exporter and an American buyer. Distinguish patent protection, generic medicines and tariff exemptions. The case also connects supply security with trade policy: a country may seek more domestic production while keeping access to particular imported treatments.

Key terms

TariffA tax on goods entering a country. The importer pays it to the importing country's authorities. An exporter may still feel the effect if buyers demand a lower price or switch suppliers. A tariff exemption removes the specified charge, not every cost of importing.

Customs value and percentage tariffCustoms value is the value used to calculate the import tax under customs rules. A percentage tariff is applied to that amount. At a 100% rate, a $100 customs value produces a $100 tariff. This calculation is different from a medicine's eventual retail price.

Patented medicineA medicine involving an invention protected by a patent. The protection lets the patent holder prevent unauthorised use of that invention for a limited period. Patent status concerns legal rights over the invention; it does not by itself decide every import duty.

Generic medicineAn approved alternative to an original medicine, with the same active ingredient and required standards of performance. Generics usually enter after relevant patent protections expire. The US measure discussed here excludes generic medicines and their associated ingredients; this is separate from the specialty-drug exemption.

Specialty medicineHere, this means a medicine within the particular categories defined in the US notice. Examples include fertility drugs and gene-therapy products. A medicine does not qualify merely because it is expensive or described as advanced. The notice's definition is what matters for the tax exemption.

Orphan drugA medicine designated for a rare disease or condition under the relevant US rules. For this tariff exemption, all its approved uses must satisfy the notice's rare-disease condition. A medicine with just one such use does not automatically pass that test.

Active pharmaceutical ingredientThe part of a medicine that produces its intended treatment effect. Other ingredients may give a tablet its shape or help deliver the active substance. Trade rules can cover these active ingredients as well as finished medicines, because manufacturers also buy ingredients across borders.

Section 232A provision of the US Trade Expansion Act of 1962 dealing with imports that may threaten national security. It allows action following the required investigation and findings. The pharmaceutical measure uses this law and links medicine supply to national security.

Sources (4)

US Department of Commerce · official · Specialty pharmaceutical tariff eligibility, 23 September 2026
US Food and Drug Administration · official · Generic drug facts
Business Standard / PTI · US exempts India and other jurisdictions from tariff on specified specialty drugs
White House · official · Pharmaceutical import proclamation, 2 April 2026